Oslo University Hospital, Ullevål, Cancer Centre, Oslo, Norway.
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1017-24. doi: 10.1016/j.ijrobp.2010.07.007. Epub 2010 Oct 6.
Preoperative chemoradiotherapy (CRT) is superior to radiotherapy (RT) in locally advanced rectal cancer, but the survival gain is limited. Late toxicity is, therefore, important. The aim was to compare late bowel, urinary, and sexual functions after CRT or RT.
Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin). Extended surgery was often required. Self-reported late toxicity was scored according to the LENT SOMA criteria in a structured telephone interview and with questionnaires European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), International Index of Erectile Function (IIEF), and sexual function-vaginal changes questionnaire (SVQ).
Of the 105 patients alive in Norway and Sweden after 4 to 12 years of follow-up, 78 (74%) responded. More patients in the CRT group had received a stoma (73% vs. 52%, p = 0.09). Most patients without a stoma (7 of 12 in CRT group and 9 of 16 in RT group) had incontinence for liquid stools or gas. No stoma and good anal function were seen in 5 patients (11%) in the CRT group and in 11 (30%) in the RT group (p = 0.046). Of 44 patients in the CRT group, 12 (28%) had had bowel obstruction compared with 5 of 33 (15%) in the RT group (p = 0.27). One-quarter of the patients reported urinary incontinence. The majority of men had severe erectile dysfunction. Few women reported sexual activity during the previous month. However, the majority did not have concerns about their sex life.
Fecal incontinence and erectile dysfunction are frequent after combined treatment for locally advanced rectal cancer. There was a clear tendency for the problems to be more common after CRT than after RT.
术前放化疗(CRT)在局部晚期直肠癌中优于放疗(RT),但生存获益有限。因此,晚期毒性很重要。本研究旨在比较 CRT 或 RT 治疗后肠道、泌尿和性功能的晚期毒性。
207 例不可切除直肠癌患者随机分为术前 CRT 或 RT(2 Gy×25 ± 5-氟尿嘧啶/亚叶酸)。通常需要进行扩大手术。采用结构化电话访谈和欧洲癌症研究与治疗组织(EORTC)生活质量问卷(QLQ-C30)、国际勃起功能指数(IIEF)和性功能-阴道变化问卷(SVQ)对自我报告的晚期毒性进行评分,采用 LENT SOMA 标准进行评分。
随访 4-12 年后,挪威和瑞典有 105 例患者存活,其中 78 例(74%)做出应答。CRT 组中更多的患者接受了造口术(73% vs. 52%,p=0.09)。大多数未造口的患者(CRT 组 12 例中有 7 例,RT 组 16 例中有 9 例)有液体粪便或气体失禁。CRT 组有 5 例(11%)和 RT 组有 11 例(30%)无造口且肛门功能良好(p=0.046)。CRT 组有 44 例患者发生肠梗阻,占 12%,而 RT 组有 33 例患者中有 5 例发生肠梗阻,占 15%(p=0.27)。四分之一的患者报告有尿失禁。大多数男性有严重的勃起功能障碍。很少有女性报告在过去一个月有性行为。然而,大多数女性对自己的性生活没有担忧。
联合治疗局部晚期直肠癌后常出现粪便失禁和勃起功能障碍。CRT 后这些问题比 RT 后更常见,有明显的趋势。